tetano
Editor, Senior Moderator
Front Immunol
. 2022 Jan 13;12:747116.
doi: 10.3389/fimmu.2021.747116. eCollection 2021.
COVID-19 Disease and Dermatomyositis: A Mini-Review
Jie Qian[SUP] 1 [/SUP], Hui Xu[SUP] 1 [/SUP]
Affiliations
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has caused a large number of deaths, and there is still no effective treatment. COVID-19 can induce a systemic inflammatory response, and its clinical manifestations are diverse. Recently, it has been reported that COVID-19 patients may develop myositis and interstitial pulmonary disease similar to dermatomyositis (DM). This condition is similar to the rapidly progressive interstitial lung disease associated with MDA5[SUP]+[/SUP] DM that has a poor prognosis and high mortality, and this poses a challenge for an early identification. Suppression of the immune system can protect COVID-19 patients by preventing the production of inflammatory cytokines. This article attempts to explore the possibility of a relationship between COVID-19 and DM in terms of the potential pathogenesis and clinical features and to analyze the therapeutic effect of the immunosuppressive drugs that are commonly used for the treatment of both DM and COVID-19.
Keywords: COVID-19; SARS-CoV-2; dermatomyositis; pathogenesis; treatment.
. 2022 Jan 13;12:747116.
doi: 10.3389/fimmu.2021.747116. eCollection 2021.
COVID-19 Disease and Dermatomyositis: A Mini-Review
Jie Qian[SUP] 1 [/SUP], Hui Xu[SUP] 1 [/SUP]
Affiliations
- PMID: 35095837
- PMCID: PMC8792859
- DOI: 10.3389/fimmu.2021.747116
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has caused a large number of deaths, and there is still no effective treatment. COVID-19 can induce a systemic inflammatory response, and its clinical manifestations are diverse. Recently, it has been reported that COVID-19 patients may develop myositis and interstitial pulmonary disease similar to dermatomyositis (DM). This condition is similar to the rapidly progressive interstitial lung disease associated with MDA5[SUP]+[/SUP] DM that has a poor prognosis and high mortality, and this poses a challenge for an early identification. Suppression of the immune system can protect COVID-19 patients by preventing the production of inflammatory cytokines. This article attempts to explore the possibility of a relationship between COVID-19 and DM in terms of the potential pathogenesis and clinical features and to analyze the therapeutic effect of the immunosuppressive drugs that are commonly used for the treatment of both DM and COVID-19.
Keywords: COVID-19; SARS-CoV-2; dermatomyositis; pathogenesis; treatment.